帕唑帕尼与多柔比星一线治疗60岁及以上转移性软组织肉瘤的随机比较:德国跨组研究结果
该随机对照研究纳入60岁及以上、未经系统治疗的晚期或转移性软组织肉瘤患者,按2:1随机接受帕唑帕尼(81例)或多柔比星(39例)。
要点
- 帕唑帕尼一线治疗老年晚期软组织肉瘤的PFS非劣于多柔比星。
- 帕唑帕尼血液学毒性(4级中性粒细胞减少和发热性中性粒细胞减少)发生率低于多柔比星。
- 总生存两组无显著差异,客观缓解率分别为12.3%和15.4%。
核心结论
- 在60岁及以上晚期软组织肉瘤患者中,帕唑帕尼一线治疗的无进展生存期非劣效于多柔比星。
- 帕唑帕尼可作为该人群一线治疗的潜在选择,其不良反应谱可用于个体化治疗决策。
研究设计与样本
- 随机对照试验,按2:1随机分配至帕唑帕尼800mg每日一次或多柔比星75mg/m2每3周一次(≤6周期)。
- 纳入60岁及以上、无既往系统治疗、ECOG体能状态0-2、器官功能适当的进展期或转移性软组织肉瘤患者。
- 帕唑帕尼组81例,多柔比星组39例;中位年龄71岁(范围60-88岁)。
主要发现
- 无进展生存期非劣效:HR 1.00(95%CI 0.65-1.53),95%CI上限低于预设非劣效界值1.8。
- 帕唑帕尼组4级中性粒细胞减少和发热性中性粒细胞减少发生率低于多柔比星组。
- 客观缓解率:帕唑帕尼组12.3%,多柔比星组15.4%。
- 老年评估显示15.8%患者有2种及以上合并症,28.3%患者日常活动能力受损。
关键数值与推荐
- 非劣效界值:PFS的HR 95%CI上限小于1.8。
- 帕唑帕尼剂量800mg每日一次;多柔比星剂量75mg/m2每3周一次,最多6周期。
临床怎么用
- 对于60岁及以上晚期软组织肉瘤患者,帕唑帕尼可作为一线治疗选择之一。
- 可根据不良反应谱(帕唑帕尼血液学毒性较低)结合患者个体需求选择治疗方案。
局限性
- 样本量较小(帕唑帕尼组81例,多柔比星组39例),可能影响统计效能。
- 仅纳入60岁及以上患者,结论不能外推至年轻人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Doxorubicin is a standard of care in patients with advanced, inoperable soft tissue sarcoma (STS). We tested whether pazopanib has efficacy comparable to that of doxorubicin in elderly patients with STS and offers superior tolerability for hematologic toxicity. PATIENTS AND METHODS: Patients age 60 years or older without previous systemic treatment for progressive advanced or metastatic STS who had Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate organ function were included. Treatment consisted of pazopanib 800 mg once per day or doxorubicin 75 mg/m2 once every 3 weeks (≤ 6 cycles) after being randomly assigned in a 2:1 ratio. Noninferiority was assumed for progression-free survival (PFS), if the upper limit of the 95% CI for the hazard ratio (HR) was less than 1.8. Neutropenia and febrile neutropenia were key secondary end points. The European Organisation for Research and Treatment of Cancer (30-item) Quality of Life Questionnaire and geriatric assessment were used to measure patient-reported outcomes. Cox regression analysis and Kaplan-Meier curves were used for analysis. RESULTS: Pazopanib and doxorubicin were given to 81 and 39 patients, respectively. The median age was 71 years (range, 60-88 years). PFS was noninferior (HR, 1.00; 95% CI, 0.65 to 1.53) and the incidence of grade 4 neutropenia and febrile neutropenia favored pazopanib. Objective response rates for pazopanib and doxorubicin were 12.3% and 15.4%, respectively. Overall survival did not differ significantly between arms (HR, 1.08; 95% CI, 0.68 to 1.72; P = .735). Geriatric assessment revealed 2 or more comorbidities in 15.8% of the patients and impairment of activities of daily living in 28.3% of patients. CONCLUSION: Pazopanib was noninferior to doxorubicin, rendering pazopanib a putative therapeutic option in the first-line treatment of STS in patients age 60 years or older. The distinct adverse event profile may be used to counsel patients and tailor therapy to individual needs.
引用
- Grünwald V, Karch A, Schuler M, et al. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. J Clin Oncol. 2020. PMID: 32840417. doi:10.1200/JCO.20.00714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。